Fierce Pharma

SEPTEMBER 28, 2023

Fabre-Kramer Pharmaceuticals' major depressive disorder (MDD) drug gepirone has been rejected by the FDA not once, not twice, but three times since the turn of the millennium. | Fabre-Kramer's Exxua suffered three prior FDA rejections before scoring an FDA approval for major depressive disorder last week. Its label doesn't include sexual dysfunction as an adverse reaction, which is rare among antidepressants.

FDA 304

FDA Pharmaceutical 304

MedCity News

SEPTEMBER 28, 2023

Sanofi dominates the market for therapies that treat Pompe disease, a rare enzyme deficiency. The FDA has approved an Amicus Therapeutics combination treatment for patients inadequately served by the Sanofi products.

FDA 120

FDA Patients Marketing Biopharma 120

Fierce Pharma

SEPTEMBER 28, 2023

Slated for an FDA decision last October, Amicus Therapeutics’ Pompe disease bid was foiled by COVID-related travel restrictions. | Slated for an FDA decision last October, Amicus Therapeutics’ Pompe disease bid was foiled by COVID-related travel restrictions. Nearly a year later, the Philadelphia company has gained its long-awaited green light.

FDA 278

FDA 278

Integrity Solutions

SEPTEMBER 28, 2023

It’s never been more important to understand your customers and what they value. It’s easy to say that we put the customer first, but what does that actually look like in practice? In the past, customer service centers were viewed as cost centers or expenses. Today, the organizations that are delivering a superior customer experience are proving just how outdated that perspective is.

Training 116

Training Sales Management Product Knowledge 116

Advertisement

When a CRO is bidding on a project where clinical supplies will be one of the aspects to manage on behalf of the client via a partner, leveraging the expertise of a chosen clinical supply partner can be a valuable resource in demonstrating the CRO’s understanding of and ability to deliver upon critical drug-supply related aspects of the project, and ability to hit key milestones such as FPI for their client.

Management

Fierce Pharma

SEPTEMBER 28, 2023

While GLP-1 drugs from Novo Nordisk and Eli Lilly are believed to be relatively free of serious side effects, a few problems have emerged as the treatments have gained wider and longer-term use.

Side effects 275

Side effects FDA 275

MedCity News

SEPTEMBER 28, 2023

New York, Florida, Texas and Minnesota terminated Medicaid coverage for some enrollees for “unallowable or potentially unallowable reasons” during the Covid-19 public health emergency, according to a recent Office of Inspector General report.

110

110

Pharmaceutical Technology

SEPTEMBER 28, 2023

The company’s algorithms put proteins through millions of years of simulated evolution to identify potential functional candidates.

126

126

Fierce Pharma

SEPTEMBER 28, 2023

A highly anticipated head-to-head matchup between a Johnson & Johnson combination and AstraZeneca’s star Tagrisso as a first-line treatment in a subset of non-small cell lung cancer (NSCLC) has | With the trial win, Johnson & Johnson sees potential for its drug combination as the new standard of care in locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer.

236

236

MedCity News

SEPTEMBER 28, 2023

C-SNPs are Medicare Advantage plans formulated to meet the desired needs of people living with chronic diseases. These plans are different from traditional Medicare plans because they’re only available to people who fit the special needs category that the plan serves.

Healthcare 102

Healthcare Healthcare Specialization Management 102

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. | Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

Sales 216

Sales 216

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

PharmaTech

SEPTEMBER 28, 2023

Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.

Patients 116

Patients 116

Fierce Pharma

SEPTEMBER 28, 2023

As bluebird bio’s pricey gene therapy launches take flight, the company is boosting manufacturing capacity with Swiss CDMO Lonza. | Bluebird and Lonza recently amended their production contract for the second time since the deal was announced in summer of 2016. Under the updated deal, Lonza has agreed to increase manufacturing capacity for bluebird’s therapies Zynteglo and Skysona, according to a SEC filing published Wednesday.

Manufacturing 214

Manufacturing 214

Copyright Clearance Center

SEPTEMBER 28, 2023

September 28, 2023 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announces the availability of AI-disambiguated data and enriched metadata, for researchers and institutions, within RightFind Navigate through a pilot for its customers. CCC also announces several powerful new features of the RightFind Suite.

Pharmaceutical 95

Pharmaceutical Management 95

Fierce Pharma

SEPTEMBER 28, 2023

AstraZeneca has made several news headlines for its environmental sustainability pledges, including deals for renewable natural gas and a commitment to plant hundreds of millions of trees. | In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions.

Pharma 208

Pharma 208

Advertisement

The sourcing of commercial drugs for use in clinical trials either as a comparator, rescue or co-medication can be a complex process. Sponsors can face a number of challenges when trying to obtain these critical supplies for their studies, including addressing product lead times, availability, expiry limitations, safety and cost, among others. Choosing the right partner with global sourcing, regulatory, quality and clinical packaging expertise can provide the necessary guidance to help sponsors

Medical

MedCity News

SEPTEMBER 28, 2023

Through a new partnership, Vori Health will be able to refer its patients who report having an opioid addiction to Ophelia. On the flip side, Ophelia can refer its patients who report having MSK pain to Vori Health for non-opioid treatment.

Patients 92

Patients 92

Fierce Pharma

SEPTEMBER 28, 2023

The FDA has signed off on Takeda’s subcutaneous version of Entyvio to be used as a maintenance therapy for patients with ulcerative colitis.

FDA 215

FDA Patients 215

PharmaTimes

SEPTEMBER 28, 2023

Collaboration will enable teams across the organisation to increase clinical research innovation - News - PharmaTimes

114

114

Fierce Pharma

SEPTEMBER 28, 2023

Dato-DXd, the TROP2-targeted antibody-drug conjugate in development by AstraZeneca and Daiichi Sankyo, has hits its goal in a breast cancer trial. | AstraZeneca and Daiichi Sankyo's TROP2-targeted antibody-drug conjugate has hits its goal in a breast cancer trial. The combination of Padcev and Keytruda also succeeded in a broad first-line bladder cancer setting.

Pharma 130

Pharma 130

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Pharmaceutical Commerce

SEPTEMBER 28, 2023

Questions and considerations for pharmaceutical companies in designing and executing strategies to curb the incidence of fake drugs.

Pharmaceutical 105

Pharmaceutical 105

European Pharmaceutical Review

SEPTEMBER 28, 2023

According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceutical manufacturing in the EEA, is implemented. A total ban [of PFAS] would see medicines’ manufacturing in the EU grind to a halt in under three years” EFPIA stated that the EU chemical legislation under The Regulation on the regist

Pharmaceutical manufacturing 87

Pharmaceutical manufacturing Pharmaceutical Manufacturing Medicine 87

PharmaTimes

SEPTEMBER 28, 2023

Initiative has been designed to support career advancement for women across the life sciences - News - PharmaTimes

108

108

PharmaVoice

SEPTEMBER 28, 2023

A recent report showed how pharma’s bonuses pale in comparison to other industries, but several execs still rake in hefty packages.

Pharma 95

Pharma 95

Advertisement

As demand for advanced therapies increases, so does the need for more specialized supply chain support, as these products have strict transportation and handling requirements. Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.

Patients

Pharmaceutical Commerce

SEPTEMBER 28, 2023

How recent advancements in practice and technology have ushered in a new era of pharmaceutical logistics.

Pharmaceutical 104

Pharmaceutical 104

European Pharmaceutical Review

SEPTEMBER 28, 2023

The US Food and Drug Administration (FDA) has approved Takeda’s single-dose pre-filled pen for ENTYVIO ® (vedolizumab) as a treatment for the chronic inflammatory disease ulcerative colitis. Subcutaneous (SC) administration is authorised for US adults with moderate to severe active ulcerative colitis (UC) after induction therapy with ENTYVIO intravenous (IV).

FDA 76

FDA Food and Drug Administration Patients Physicians 76

MedCity News

SEPTEMBER 28, 2023

For the September episode, we discuss some recent executive appointments occurring in the healthcare sector, as well as layoffs affecting the industry. We also hear from Chris Allen, who recently became CFO at Keck Medicine of USC.

Medicine 76

Medicine Healthcare Healthcare 76

European Pharmaceutical Review

SEPTEMBER 28, 2023

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre. Known as MITC, or the Moderna Innovation and Technology Centre, the facility is located in Harwell, Oxfordshire and is expected to become operational in 2025.

Manufacturing 75

Manufacturing Pharmaceutical manufacturing Pharmaceutical Pharma 75

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

PharmExec

SEPTEMBER 28, 2023

Lakdawalla speaks about how drugs aren’t being properly valued.

110

110

PharmaVoice

SEPTEMBER 28, 2023

As Medicare negotiations heat up, it’s more important than ever for pharma companies to communicate their value. Here’s how.

Pharma 72

Pharma Marketing 72

MedTechVets

SEPTEMBER 28, 2023

SEP 28th – We were proud to interview MedTechVet Academy Mentor, Grant Cox. Grant is currently the Vice President of Operations at Z Construction. He recently was going through the Fire Academy in Greenville, SC to become a Firefighter, but was medically released after having surgery on both of his hips.Grant is a huge believer in medicine and believes that better days are ahead of him. “With strong faith, a goal in mind and a purpose, you can get through anything.

Medical 59

Medical Pharmaceutical Medicine Recruitment 59

MedCity News

SEPTEMBER 28, 2023

Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.

Healthcare 76

Healthcare Healthcare Medicine Pharmaceutical 76

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition